Bambusa Therapeutics

Private

Clinical-stage biotechnology company developing next-generation bispecific antibodies for immunology and inflammation (I&I) disorders, including dermatology, respiratory, gastroenterology and rheumatology.

Company Info

Sector:Antibodies

Headquarters:Boston, MA, USA

Founded:2024

Website:bambusatx.com/

Funding Round:Series A (February 2025) followed by Series A-2 (November 2025)

Total Funding:~$90M Series A

Funding & Investor Relations

Notable Investors

RA Capital Management

IPO Outlook / Plans

Confidentially filed with the SEC for an initial public offering; terms not yet set.

Clinical Development Pipeline

BBT001

Target: IL-4R alpha x IL-31

Atopic dermatitis and other Type 2 inflammatory skin conditions

Preclinical

Phase 1

Phase 2

Phase 3

Approved

BBT002

Target: Bispecific antibody

Immunological and inflammatory disorders

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Recent News

No recent news updates available for this company.

Leadership Team

Shanshan Xu

Co-founder

Helmut Jeggle

Co-founder

Careers & Job Openings

See all open roles

All

Boston, MA

Apply Now →